Moderna Stock Rises Sharply After Positive News on Cancer Vaccine
Following positive Phase-3 study results for its personalized cancer vaccine, Moderna's stock rose nearly 130%. The vaccine, "Intismeran autogene," combined with Keytruda significantly reduced recurrence risk in malignant melanoma patients, signaling major growth potential for the company.
Moderna's shares recorded a dramatic increase following the release of positive study results for a new, personalized cancer vaccine developed by the company in collaboration with Merck. The vaccine, named "Intismeran autogene," is designed to address the specific genetic structure of the tumor. One thousand one hundred patients with malignant melanomas were examined in a Phase 3 study. The combination of this new vaccine with Keytruda showed significant potential by significantly reducing the risk of recurrence or death. This breakthrough reflects the market's enthusiasm and positions Moderna for considerable growth potential beyond its established portfolio of COVID-19 vaccines. Experts view this progress as a major milestone for the company's future market role.